Galderma Bags Health Canada Approval For Restylane Shaype

India Pharma Outlook Team | Tuesday, 23 January 2024

 India Pharma Outlook Team

Galderma, an emerging leader in the pure-play dermatology category, announced that it has received approval from Health Canada for Restylane Shaype, an injectable hyaluronic acid (HA) solution for temporary augmentation of the chin area. Restylane Shaype is designed to build and shape by injecting deep into the bone with a bone-mimicking effect and will be available in Canada starting in February 2024.

The chin is a critical component of overall appearance that influences the balance of facial proportions, profile, and shape. Genetics and age can impact overall chin definition, which may cause the appearance of a double chin, or “weak chin.” For decades, there has been heavy reliance on implants to create structure in the lower face, with no non-surgical options available offering qualities close to an implant, as per pharmabiz.

Galderma's new Nasha HD technology Restylane Shaype is the highest G' ("G prime") of the Restylane series. Restylane Shaype, the strongest HA gel on the market, allows you to shape, project and lengthen the chin with aesthetic injections for a natural-looking result from any angle. As a lightly modified and extra solid HA gel, Restylane Shaype is the closest thing to injectable HA that occurs naturally in the skin and can be easily reversed..

“Restylane Shaype is the next generation in HA, going beyond currently available options for chin augmentation. Developed with leading experts, this innovative breakthrough has a unique ability to create the strength and support needed for a bone-mimicking effect. This makes Restylane Shaype an ideal choice for lower face shaping, offering durable, natural-looking results for up to 12 months without retreatment,” said Baldo Scassellati Sforzolini, M.D., Ph.D., global head of R&D, Galderma.

© 2024 India Pharma Outlook. All Rights Reserved.